Price$0.96+0.02 (+2.12%)
01:30 PM07:45 PM
News · 26 weeks36+200%
2026-03-012026-08-23
Mix990d
- Earnings4(44%)
- SEC Filings3(33%)
- Other2(22%)
Latest news
25 items- PRPAVmed Provides Business Update and Reports Second Quarter 2026 Financial ResultsVeris Health accelerated its commercial engagement with OSU-The JamesVeris Health implantable physiological monitor achieved development milestones towards upcoming FDA submissionLucid Diagnostics secured first laboratory benefit manager coverage policy for EsoGuard ®Conference call and webcast to be held today, August 14, at 8:30 AM EDTNEW YORK, Aug. 14, 2026 /PRNewswire/ -- PAVmed Inc. (NASDAQ:PAVM) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company operating in the medical device, diagnostics, and digital health sectors, today provided a business update for the Company and its subsidiaries, Lucid Diagnostics Inc. (NASDAQ:LUCD) ("Lucid"), Veris Health In
- SECLucid Diagnostics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition8-K - Lucid Diagnostics Inc. (0001799011) (Filer)
- PRLucid Diagnostics Provides Business Update and Reports Second Quarter 2026 Financial ResultsRecognized 2Q26 revenue of $1.5 millionProcessed 2,770 EsoGuard ® testsSecured first laboratory benefit manager (LBM) EsoGuard coverage policyConference call and webcast to be held today, August 13, at 8:30 AM EDTNEW YORK, Aug. 13, 2026 /PRNewswire/ -- Lucid Diagnostics Inc. (NASDAQ:LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (NASDAQ:PAVM) ("PAVmed"), today provided a business update for the Company and reported financial results for the second quarter ended June 30, 2026. Conference Call and WebcastThe webcast will take place on Thursday, Aug
- SECSEC Form 10-Q filed by Lucid Diagnostics Inc.10-Q - Lucid Diagnostics Inc. (0001799011) (Filer)
- PRLucid Diagnostics Secures Commercial Coverage Policy Spanning Multiple Health Plans for its EsoGuard® Esophageal DNA TestConcert's policy recognizes EsoGuard ® as the only esophageal precancer test meeting its coverage criteriaNEW YORK, Aug. 5, 2026 /PRNewswire/ -- Lucid Diagnostics Inc. (NASDAQ:LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (NASDAQ:PAVM), today announced that Concert, a healthcare technology company recently acquired by Lyric, issued a positive coverage policy effective July 2026 for non-invasive screening of esophageal precancer and cancer. Concert establishes coverage policies that its client health plans can adopt. The policy cites sufficient e
- PRLucid Diagnostics to Participate in Upcoming Investor ConferencesNEW YORK, Aug. 4, 2026 /PRNewswire/ -- Lucid Diagnostics Inc. (NASDAQ:LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (NASDAQ:PAVM), today announced that management will participate in the following upcoming investor conferences: 11th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference 1x1 Meetings: August 10, 2026Location: VirtualCanaccord Genuity 46th Annual Growth Conference Fireside Chat: August 11, 2026, at 11:30 AM ETLocation: Boston, MAThe live and archived webcast of the Canaccord Genuity fireside chat can be accessed by clicking
- PRPAVmed to Hold Second Quarter 2026 Business Update Conference Call and Webcast on August 14, 2026Conference Call and Webcast at 8:30 AM ETNEW YORK, July 31, 2026 /PRNewswire/ -- PAVmed Inc. (NASDAQ:PAVM) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today announced that it will host a business update conference call and webcast on Friday, August 14, 2026, at 8:30 AM ET. During the call, Lishan Aklog, M.D., PAVmed's Chairman and Chief Executive Officer, will provide a business update and discuss the Company's operations and growth strategy. In addition, Dennis McGrath, PAVmed's President and Chief Financial Officer, will discuss the Company's second quarter 2026 financial r
- PRLucid Diagnostics to Hold Second Quarter 2026 Business Update Conference Call and Webcast on August 13, 2026Conference Call and Webcast at 8:30 AM ETNEW YORK, July 30, 2026 /PRNewswire/ -- Lucid Diagnostics Inc. (NASDAQ:LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (NASDAQ:PAVM), today announced that it will host a business update conference call and webcast on Thursday, August 13, 2026, at 8:30 AM ET. During the call, Lishan Aklog, M.D., Lucid's Chairman and Chief Executive Officer, will provide a business update and discuss the Company's operations and growth strategy. In addition, Dennis McGrath, Lucid's Chief Financial Officer, will discuss the Company's second quarter 2026 financial results.
- SECLucid Diagnostics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - Lucid Diagnostics Inc. (0001799011) (Filer)
- INSIDERDirector Matheis Dennis bought $245,270 worth of shares (245,000 units at $1.00), increasing direct ownership by 31% to 1,033,443 units (SEC Form 4)4 - Lucid Diagnostics Inc. (0001799011) (Issuer)
- PRPAVmed Provides Business Update and Reports First Quarter 2026 Financial ResultsVeris Health progressed commercial expansion and advanced implantable physiological monitor development toward FDA submissionLucid Diagnostics continued building commercial momentum and strengthened its balance sheet ahead of key upcoming reimbursement milestonesPAVmed advanced its relaunched medical device portfolio; evaluation of additional acquisition opportunities ongoingConference call and webcast to be held today, May 15, at 8:30 AM EDTNEW YORK, May 15, 2026 /PRNewswire/ -- PAVmed Inc. (NASDAQ:PAVM) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today provided a business u
- SECLucid Diagnostics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Lucid Diagnostics Inc. (0001799011) (Filer)
- PRLucid Diagnostics Provides Business Update and Reports First Quarter 2026 Financial ResultsProcessed 3,177 EsoGuard® tests and recognized 1Q26 revenue of $1.3 million, ending quarter with $45 million in proforma cash and a runway that extends into 2027 and past upcoming reimbursement milestonesConference call and webcast to be held today, May 14, at 8:30 AM EDTNEW YORK, May 14, 2026 /PRNewswire/ -- Lucid Diagnostics Inc. (NASDAQ:LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (NASDAQ:PAVM) ("PAVmed"), today provided a business update for the Company and reported financial results for the first quarter ended March 31, 2026.
- SECSEC Form 10-Q filed by Lucid Diagnostics Inc.10-Q - Lucid Diagnostics Inc. (0001799011) (Filer)
- PRPAVmed to Hold First Quarter 2026 Business Update Conference Call and Webcast on May 15, 2026Conference Call and Webcast at 8:30 AM ETNEW YORK, May 1, 2026 /PRNewswire/ -- PAVmed Inc. (NASDAQ:PAVM) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today announced that it will host a business update conference call and webcast on Friday, May 15, 2026, at 8:30 AM ET. During the call, Lishan Aklog, M.D., PAVmed's Chairman and Chief Executive Officer, will provide a business update and discuss the Company's operations and growth strategy. In addition, Dennis McGrath, PAVmed's President and Chief Financial Officer, will discuss the Company's first quarter 2026 financial results
- SECSEC Form DEFA14A filed by Lucid Diagnostics Inc.DEFA14A - Lucid Diagnostics Inc. (0001799011) (Filer)
- SECSEC Form DEF 14A filed by Lucid Diagnostics Inc.DEF 14A - Lucid Diagnostics Inc. (0001799011) (Filer)
- PRLucid Diagnostics to Hold First Quarter 2026 Business Update Conference Call and Webcast on May 14, 2026Conference Call and Webcast at 8:30 AM ETNEW YORK, April 30, 2026 /PRNewswire/ -- Lucid Diagnostics Inc. (NASDAQ:LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (NASDAQ:PAVM), today announced that it will host a business update conference call and webcast on Thursday, May 14, 2026, at 8:30 AM ET. During the call, Lishan Aklog, M.D., Lucid's Chairman and Chief Executive Officer, will provide a business update and discuss the Company's operations and growth strategy. In addition, Dennis McGrath, Lucid's Chief Financial Officer, will discuss the Company's first quarter 2026 financial results.
- INSIDERAmendment: New insider Lee Victoria Tou-Ho claimed ownership of 650,000 shares (SEC Form 3)3/A - Lucid Diagnostics Inc. (0001799011) (Issuer)
- SECLucid Diagnostics Inc. filed SEC Form 8-K: Regulation FD Disclosure8-K - Lucid Diagnostics Inc. (0001799011) (Filer)
- PRLucid Diagnostics Announces Closing of $18 Million Underwritten Offering of Common StockNEW YORK, April 24, 2026 /PRNewswire/ -- Lucid Diagnostics Inc. (NASDAQ:LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (NASDAQ:PAVM), today announced the closing of its previously announced underwritten registered direct offering of 18,000,000 common shares at a purchase price of $1.00 per share, anchored by a $15 million investment from a fundamental institutional investor with support from a large existing shareholder. The gross proceeds from the offering, before deducting underwriting discount
- SECSEC Form 424B5 filed by Lucid Diagnostics Inc.424B5 - Lucid Diagnostics Inc. (0001799011) (Filer)
- SECLucid Diagnostics Inc. filed SEC Form 8-K: Regulation FD Disclosure8-K - Lucid Diagnostics Inc. (0001799011) (Filer)
- PRLucid Diagnostics Announces $18 Million Underwritten Offering of Common StockNEW YORK, April 23, 2026 /PRNewswire/ -- Lucid Diagnostics Inc. (NASDAQ:LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (NASDAQ:PAVM), today announced the pricing of an underwritten registered direct offering of 18,000,000 common shares at a purchase price of $1.00 per share, anchored by a $15M investment from a fundamental institutional investor with support from a large existing shareholder. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other e
- SECSEC Form PRE 14A filed by Lucid Diagnostics Inc.PRE 14A - Lucid Diagnostics Inc. (0001799011) (Filer)
LUCD FAQ
7 questionsWhat does Lucid Diagnostics Inc. do?
Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company. It focuses on patients with gastroesophageal reflux disease, also known as chronic heartburn, acid reflux or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma. The company's lead products include EsoGuard, a laboratory developed esophageal DNA test that examines individuals DNA molecules for the presence or absence of cytosine methylation; and EsoCheck, a cell collection device that collects cells of targeted region of...Where does LUCD stock trade?
Lucid Diagnostics Inc. (LUCD) is listed on NASDAQ.What sector and industry is LUCD in?
Lucid Diagnostics Inc. operates in the Health Care sector, Medical/Dental Instruments industry.When did Lucid Diagnostics Inc. go public?
Lucid Diagnostics Inc. (LUCD) completed its IPO in 2021.What are analysts saying about LUCD?
Lucid Diagnostics Inc. has had 6 recent analyst actions on file. The most recent action was from Ascendiant Capital: Buy with a $1600.00 price target on 2021-12-27. Recent price targets range from $1300.00 to $2100.00.What companies are similar to LUCD?
Notable peers in the same industry include SYK (Stryker Corporation), MMM (3M Company), BSX (Boston Scientific Corporation), BDX (Becton Dickinson and Company), MDLN (Medline Inc.). Compare LUCD side-by-side with any of them on Quantisnow.How can I track LUCD on Quantisnow?
Quantisnow aggregates Lucid Diagnostics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow LUCD to receive live email and push alerts on every new disclosure.